These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 25911438)

  • 1. Analgesic use before and after oral anticoagulant initiation--a population-based study in Finland.
    Ilomäki J; Helin-Salmivaara A; Huupponen R; Rikala M; Kirkpatrick CM; Korhonen MJ
    Eur J Clin Pharmacol; 2015 Jun; 71(6):723-732. PubMed ID: 25911438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
    Olesen JB; Sørensen R; Hansen ML; Lamberts M; Weeke P; Mikkelsen AP; Køber L; Gislason GH; Torp-Pedersen C; Fosbøl EL
    Europace; 2015 Feb; 17(2):187-93. PubMed ID: 25236181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States.
    Lip GY; Pan X; Kamble S; Kawabata H; Mardekian J; Masseria C; Bruno A; Phatak H
    Int J Clin Pract; 2016 Sep; 70(9):752-63. PubMed ID: 27550177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis.
    Chan KE; Edelman ER; Wenger JB; Thadhani RI; Maddux FW
    Circulation; 2015 Mar; 131(11):972-9. PubMed ID: 25595139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY; Larsen TB; Skjøth F; Rasmussen LH
    J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.
    Abraham NS; Singh S; Alexander GC; Heien H; Haas LR; Crown W; Shah ND
    BMJ; 2015 Apr; 350():h1857. PubMed ID: 25910928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study.
    Chang HY; Zhou M; Tang W; Alexander GC; Singh S
    BMJ; 2015 Apr; 350():h1585. PubMed ID: 25911526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the Initiation of Novel Oral Anticoagulants in Medicare Beneficiaries.
    Baik SH; Hernandez I; Zhang Y
    J Manag Care Spec Pharm; 2016 Mar; 22(3):281-92. PubMed ID: 27003558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation.
    Forslund T; Wettermark B; Hjemdahl P
    Eur J Clin Pharmacol; 2016 Mar; 72(3):329-38. PubMed ID: 26613954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation.
    Larsen TB; Gorst-Rasmussen A; Rasmussen LH; Skjøth F; Rosenzweig M; Lip GY
    Am J Med; 2014 Jul; 127(7):650-656.e5. PubMed ID: 24530792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Newly Diagnosed Atrial Fibrillation.
    Hernandez I; Zhang Y; Saba S
    Am J Cardiol; 2017 Nov; 120(10):1813-1819. PubMed ID: 28864318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S; Ansell J
    Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin.
    Davidson BL; Verheijen S; Lensing AW; Gebel M; Brighton TA; Lyons RM; Rehm J; Prins MH
    JAMA Intern Med; 2014 Jun; 174(6):947-53. PubMed ID: 24733305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors driving the use of warfarin and non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
    Hu MM; Wang J; Chien KL; Su CL; Lin SY; Wu FL; Lin ZF
    J Formos Med Assoc; 2017 Apr; 116(4):276-286. PubMed ID: 27424804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in oral anticoagulant use in Qatar: a 5-year experience.
    Elewa H; Alhaddad A; Al-Rawi S; Nounou A; Mahmoud H; Singh R
    J Thromb Thrombolysis; 2017 Apr; 43(3):411-416. PubMed ID: 28138812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
    Graham DJ; Reichman ME; Wernecke M; Zhang R; Southworth MR; Levenson M; Sheu TC; Mott K; Goulding MR; Houstoun M; MaCurdy TE; Worrall C; Kelman JA
    Circulation; 2015 Jan; 131(2):157-64. PubMed ID: 25359164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Concomitant use of warfarin, analgesics and anti-inflammatory agents].
    Håkonsen GD; Pettersen MH; Skurtveit S; Giverhaug T
    Tidsskr Nor Laegeforen; 2009 Jun; 129(12):1217-20. PubMed ID: 19521444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug interactions and risk of acute bleeding leading to hospitalisation or death in patients with chronic atrial fibrillation treated with warfarin.
    Gasse C; Hollowell J; Meier CR; Haefeli WE
    Thromb Haemost; 2005 Sep; 94(3):537-43. PubMed ID: 16268469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.